Gordon Wishart

{{Infobox scientist

| name = Professor Gordon C Wishart

| birth_date = {{birth date and age|df=y|1960|09|03}}

| birth_place = Edinburgh, Scotland

| death_date =

| death_place =

| death_cause =

| nationality = Scottish

| field = Medicine, oncology, surgical oncology

| work_institution = Royal College of Surgeons of Glasgow, Royal College of Surgeons of England, Addenbrooke’s Hospital, Cambridge, University of Cambridge, Anglia Ruskin School of Medicine

| alma_mater = University of Edinburgh

| known_for = Diagnosis and treatment of breast cancer, development of [https://breast.predict.nhs.uk/ Predict cancer survival model], founder of [https://www.check4cancer.com/ Check4Cancer Ltd]

}}

Professor Gordon C. Wishart FRCS (Eng.) FRCS (Gen.) (3 September 1960-) is the founder, Chief Medical Officer, and CEO of [https://www.check4cancer.com/ Check4Cancer], an early cancer detection and prevention organisation . In 2016, Check4Cancer launched rapid access, streamlined, and audited diagnostic pathways for breast and skin cancer for the insured and self-pay markets, leading to the award of “Diagnostic Provider of the Year” at the annual Health Investor Awards in 2018. In late 2017, Check4Cancer launched the first worldwide breast cancer risk test ([https://www.check4cancer.com/private-cancer-tests/mybreastrisk MyBreastRisk]) to combine genetic, family history, and lifestyle risk factors to underpin a risk-stratified breast screening programme.

As the former Director of the [https://www.cuh.nhs.uk/cambridge-breast-unit Cambridge Breast Unit] from 2005-2010, and current Professor of Cancer Surgery at Anglia Ruskin School of Medicine since 2008, he has contributed to clinical research and modernisation of cancer diagnosis and treatment, with more than 100 peer-reviewed papers in scientific journals. In 2010, he led a team of clinicians and scientists that developed the [https://breast.predict.nhs.uk/ PREDICT breast cancer] treatment and survival model, which is now used worldwide.

Early life and education

Gordon Cranston Wishart was born in Edinburgh, Scotland, on 3 September 1960.{{Citation needed|date=June 2024}}

He studied at the University of Edinburgh Medical School, where he received his MB ChB in July 1983. He subsequently obtained his MD from the University of Edinburgh in June 1992 with a thesis entitled Aspects of multidrug resistance in breast cancer.{{Cite journal|last=Wishart|first=Gordon|date=1992|title=Aspects of multidrug resistance in breast cancer|hdl=1842/20307 |url=https://www.era.lib.ed.ac.uk/handle/1842/20307|language=en}}

Research and publications

Wishart is notable for his prolific clinical research output, alongside his work as a practising breast and endocrine surgeon.

He has received the following prizes as recognition for his scientific contribution:

Best paper: British Association of Day Surgery, 2002{{Cite web |url=http://www.selectmysurgeon.com/profile/Breast/Gordon_Wishart/ |title=Select My Surgeon - Gordon Wishart Profile |access-date=28 October 2009 |archive-url=https://web.archive.org/web/20110716034845/http://www.selectmysurgeon.com/profile/Breast/Gordon_Wishart/ |archive-date=16 July 2011 |url-status=dead }}
British Journal of Surgery Prize for best paper at British Association of Endocrine Surgeons, September 2006[https://archive.today/20130105174026/http://www3.interscience.wiley.com/journal/116324583/abstract Wiley Interscience]
British Journal of Surgery Prize for best paper at British Association of Endocrine Surgeons, September 2007http://www.baes.info/Pages/newsletter_November_2007.pdf British Association of Endocrine and Thyroid Surgeons, Newsletter, November 2007

As of October 2009, he is principal investigator on the following studies:

Reasons for improved survival in screen-detected breast cancer
Development of a UK version of Adjuvantonline.
Infrared Imaging for breast cancer diagnosis
BT blood test for breast cancer detection

In addition, he is a co-investigator, surgical coordinator, or clinical surgical coordinator on an additional 15 research studies.[http://www.selectmysurgeon.com/documents/answers/member_details_1317-CV2009.doc Gordon Wishart’s CV on Select My Surgeon]{{Dead link|date=December 2019 |bot=InternetArchiveBot |fix-attempted=yes }}

His research has been published in The Lancet,The importance, availability and measurement of oestrogen receptor (ER) status in the management of breast cancer in the United Kingdom – results of a nationwide survey. BJ Mander, K Heal, AD Purushotham, GC Wishart. The Lancet 1998; 352: 36-37 the British Journal of Cancer,GC Wishart, JA Plumb, JJ Going, AM McNicol, CS McArdle, T Tsuruo, SB Kaye. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 1990; 62: 758-761T Barrett, D J Bowden, D C Greenberg, C H Brown, G C Wishart, P D Britton. Radiological staging in breast cancer: which asymptomatic patients to image and how. British Journal of Cancer, 29 September 2009S J Dawson, S W Duffy, F M Blows, K E Driver, E Provenzano, J LeQuesne, D C Greenberg, P Pharoah, C Caldas, G C Wishart. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009; 101: 1338-1344L Hughes-Davies, C Caldas, G C Wishart. Tamoxifen: the drug that came in from the cold. British Journal of Cancer 2009; 101: 875-878G C Wishart, D C Greenberg, P D Britton, P Chou, C H Brown, A D Purushotham, S W Duffy. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? British Journal of Cancer 2008; 98: 1741-1744 the British Medical Journal,BJ Mander, GH Cunnick, M Daultrey, GC Wishart. Medical and psychological effects of early discharge after surgery for breast cancer. BMJ 1998; 317: 1081-1082 the Journal of Clinical Oncology,GC Wishart, D Bissett, J Paul, D Jodrell, A Harnett, T Habeshaw, DJ Kerr, MA Macham, M Soukop, RC Leonard. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial J Clin Oncol, 1 September 1994: 1771-1777 and the British Journal of Surgery.Gurnell E.M., Thomas S.K., McFarlane I., Munday I., Balan K.K., Berman L., Chatterjee V.K.K., Wishart G.C. Focused parathyroid surgery with intraoperative parathyroid hormone measurement as a day-case procedure. British Journal of Surgery 2004, 91(1), pp. 78-82

Gupta, Y, Ahmed, R, Happerfield, L, Pinder, SE, Balan, KK, Wishart, GC. P-glycoprotein expression is associated with sestamibi washout in primary hyperparathyroidism. British Journal of Surgery, 2007. 94(12) pp. 1491-1495

Major achievements

In 1990, Wishart identified that P-glycoprotein, a trans-membrane export pump involved in multidrug resistance, was present in breast cancer.GC Wishart, JA Plumb, JJ Going, AM McNicol, CS McArdle, T Tsuruo, SB Kaye. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 1990; 62: 758-761
In 1998, Wishart introduced early patient discharge, with wound drains still in situ, following breast cancer surgery. Although controversial at the time, this technique has since been widely adopted.BJ Mander, GH Cunnick, M Daultrey, GC Wishart. Medical and psychological effects of early discharge after surgery for breast cancer. BMJ 1998; 317: 1081-1082
Wishart pioneered minimally invasive parathyroid surgery as a daycase procedure in the UK, together with the use of intraoperative parathyroid hormone (PTH) measurement for parathyroid surgery.Gurnell EM, Thomas SK, McFarlane I, Munday I, Balan KK, Berman L, Chatterjee VKK, Wishart GC. Focused parathyroid surgery with intraoperative parathyroid hormone measurement as a day-case procedure. British Journal of Surgery 2004, 91(1), pp. 78-82
In 2007, Wishart piloted gold seed insertion following breast conserving surgery for breast cancer to facilitate targeted radiotherapy.Gold Seed Study: Evaluation of Tumour Bed Localisation and Image-guided Radiotherapy for Breast Cancer. On Behalf Of The Import Working Party, Coles CE, Wishart G, Donovan E, Harris E, Poynter A, Twyman N, Routsis D, Wilkinson J, Yarnold J. Clin Oncol (R Coll Radiol). 2007 Apr;19(3):S26-7.
In 2009, Wishart pioneered preoperative axillary lymph node staging in breast cancer treatment.Britton PD, Goud A, Godward S, Barter S, Freeman A, Gaskarth M, Rajan P, Sinnatamby R, Slattery J, Provenzano E, O’Donovan M, Pinder S , Benson J, Forouhi P, Wishart GC. Use of ultrasound-guided axillary node core biopsy in staging of early breast cancer. European Radiology 2009; 19: 561-569Britton P D, Provenzano E, Barter S, Gaskarth M, Goud A, Moyle P, Sinnatamby R, Wallis M, Benson J R, Forouhi P, Wishart GC. Ultrasound-guided percutaneous axillary lymph node core biopsy: how often is the sentinel lymph node being biopsied? The Breast 2009; 18(1): 13-16.

Current posts

Gordon Wishart currently holds the following posts:

Medical Director, BreastHealth UK[http://www.breasthealthuk.com/newsmenu/1-latest-news/213-breast-cancer-risk-for-daughters Breast Cancer Risk for Daughters]
Visiting Professor of Cancer Surgery, Anglia Ruskin University[http://www.anglia.ac.uk/ruskin/en/home/faculties/fhsc/news/press_releases/news_archive/pink_rose_appeal.html Anglia Ruskin University – Pink Rose Appeal]
Associate Lecturer, Faculty of Clinical Medicine, University of Cambridge[http://www.admin.cam.ac.uk/reporter/2005-06/weekly/6044/32.html University of Cambridge – Graces to be submitted to the Regent House at a Congregation on 22 July 2006]

He also acts as a referee for the British Journal of Surgery, the European Journal of Surgical Oncology, and Nuclear Medicine Communications.{{citation needed|date=August 2016}}

References

External links

[https://www.check4cancer.com/ Check4Cancer]
[http://www.cuh.org.uk/addenbrookes/services/clinical/breast_unit/breast_unit_index.html Cambridge Breast Unit]

Category:20th-century Scottish medical doctors

Category:21st-century Scottish medical doctors

Category:1960 births

Category:Living people

Category:Alumni of the University of Edinburgh

Category:20th-century surgeons

Category:21st-century surgeons